tradingkey.logo
tradingkey.logo
Buscar

GSK plc

GSK
Añadir a la lista de seguimiento
52.500USD
+0.600+1.16%
Cierre 06/26, 16:00ETCotizaciones retrasadas 15 min
106.44BCap. mercado
13.53P/E TTM

Más Datos de GSK plc Compañía

GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.

Información de GSK plc

Símbolo de cotizaciónGSK
Nombre de la empresaGSK plc
Fecha de salida a bolsaMay 22, 1972
Director ejecutivoWaterhouse (Deborah)
Número de empleados68629
Tipo de seguridadDepository Receipt
Fin del año fiscalMay 22
Dirección980 Great West Road
CiudadBRENTFORD
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited Kingdom
Código postalTW8 9GS
Teléfono442080475000
Sitio Webhttps://www.gsk.com/
Símbolo de cotizaciónGSK
Fecha de salida a bolsaMay 22, 1972
Director ejecutivoWaterhouse (Deborah)

Ejecutivos de GSK plc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Hal V. Barron, M.D.
Dr. Hal V. Barron, M.D.
Non-Executive Director
Non-Executive Director
602.23K
+0.01%
Ms. Shobie Ramakrishnan
Ms. Shobie Ramakrishnan
Chief Digital and Technology Officer
Chief Digital and Technology Officer
514.11K
+0.12%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
43.08K
+4.31%
Ms. Elizabeth McKee (Liz) Anderson
Ms. Elizabeth McKee (Liz) Anderson
Independent Non-Executive Director
Independent Non-Executive Director
4.24K
+18.60%
Dr. Jeannie Lee
Dr. Jeannie Lee
Independent Non-Executive Director and Scientific & Medical Expert
Independent Non-Executive Director and Scientific & Medical Expert
2.80K
+28.62%
Mr. David S. Redfern
Mr. David S. Redfern
President - Corporate Development
President - Corporate Development
--
--
Ms. Victoria Anne Whyte
Ms. Victoria Anne Whyte
Company Secretary
Company Secretary
--
--
Mr. Phil C. Thomson
Mr. Phil C. Thomson
President - Global Affairs
President - Global Affairs
--
--
Dame Emma N. Walmsley
Dame Emma N. Walmsley
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Luke Miels
Mr. Luke Miels
Chief Executive Officer - Designate, Director
Chief Executive Officer - Designate, Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Hal V. Barron, M.D.
Dr. Hal V. Barron, M.D.
Non-Executive Director
Non-Executive Director
602.23K
+0.01%
Ms. Shobie Ramakrishnan
Ms. Shobie Ramakrishnan
Chief Digital and Technology Officer
Chief Digital and Technology Officer
514.11K
+0.12%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
43.08K
+4.31%
Ms. Elizabeth McKee (Liz) Anderson
Ms. Elizabeth McKee (Liz) Anderson
Independent Non-Executive Director
Independent Non-Executive Director
4.24K
+18.60%
Dr. Jeannie Lee
Dr. Jeannie Lee
Independent Non-Executive Director and Scientific & Medical Expert
Independent Non-Executive Director and Scientific & Medical Expert
2.80K
+28.62%
Mr. David S. Redfern
Mr. David S. Redfern
President - Corporate Development
President - Corporate Development
--
--

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de GSK plc?

Los cinco principales accionistas de GSK plc son: Dr. Hal V. Barron, M.D.

¿Cuántas instituciones poseen acciones de GSK plc (GSK)?

A fecha de 2026Q1, 1585 instituciones poseen acciones de GSK plc, con un valor de mercado combinado de aproximadamente 393.46M, lo que representa el 19.40% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -23489904.00.

¿Cuál es la mayor fuente de ganancias de GSK plc?

El 2026Q1, el segmento empresarial HIV generó la ganancia más alta para GSK plc, ascendiendo a 10.12B y representando el 23.53% de la ganancia total.
KeyAI